Business
Aclarion Provides Update on Strength of Company Positioning Following Q1 Strategic Initiatives
Over $20M raised in Q1 with nearly $15M cash on hand No debt, no preferred equity, and no warrants with strike prices near the current market Nasdaq compliant: fully meets bid price and shareholder equity requirements Pivotal CLARITY trial fully funded with initial interim results expected in Q2 2026 BROOMFIELD, Colo., March 31, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprieta
About this update from Aclarion, Inc.
[{"type":"image","alt":"Aclarion, Inc.","displaySize":"","headline":null,"caption":"Aclarion, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":140,"height":83,"url":"https://media.zenfs.com/en/globenewswire.com/ba6de721dd8ef6e3bce232e051476ebf"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/JqjNbxSKpdl2ksI_nXtiLg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTEyNTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/ba6de721dd8ef6e3bce232e051476ebf","width":140,"height":83}},"lazy":false},{"type":"text","content":"Over $20M raised in Q1 with nearly $15M cash on hand","length":52,"tagName":"p"},{"type":"text","content":"No debt, no preferred equity, and no warrants with strike prices near the current market","length":88,"tagName":"p"},{"type":"text","content":"Nasdaq compliant: fully meets bid price and shareholder equity requirements ","length":75,"tagName":"p"},{"type":"text","content":"Pivotal CLARITY trial fully funded with initial interim results expected in Q2 2026","length":83,"tagName":"p"},{"type":"text","content":"BROOMFIELD, Colo., March 31, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today provided a corporate update on its strengthened positioning following the successful execution of strategic initiatives in Q1 2025.","length":454,"tagName":"p"},{"type":"text","content":"“Aclarion significantly improved its financial and Nasdaq compliance positioning throughout Q1 such that we are now very well positioned to execute on our strategic plan of driving Nociscan to standard of care,” said Jeff Thramann, MD, Executive Chairman of Aclarion. “The team is rapidly enrolling sites for the CLARITY trial, and we look forward to demonstrating that the use of Nociscan data improves surgical decision making and outcomes. We believe this will be a game changing catalyst for Aclarion and for how chronic low back pain is evaluated and treated.”","length":565,"tagName":"p"},{"type":"text","content":"Key Financial and Strategic Highlights:","length":39,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Over $20 million raised in Q1 with nearly $15 million in cash on hand","leng...